Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Top 20 Shareholders

Share Price

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Investor Centre

Clinical Trial

Webinars

Pipeline

Home

Contact

Team

Company Overview

Board

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has received A$3.77 million under the Australian Government’s Research and Development Tax Incentive program for the financial year ended 31 March 2025.

The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with a tax offset of 43.5%-48.5% (refundable) for eligible expenditure on R&D activities.

The refund relates to R&D expenditure for the development of the Company’s FAK inhibitors, including work undertaken as part of the ACCENT Phase 1b/2a clinical trial of narmafotinib (AMP945) in advanced pancreatic cancer.

These funds will be used to support the ongoing progression of the ACCENT and AMPLICITY trials, as well as further R&D activities.

Amplia Receives R&D Tax Rebate totalling $ 3.77 million